Clinical Trial
doi: 10.1023/a:1005548619694.Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder
Affiliations
- PMID:11055460
- DOI: 10.1023/a:1005548619694
Item in Clipboard
Clinical Trial
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder
B L Handen et al. J Autism Dev Disord.2000 Jun.
Display options
Format
Display options
Format
Abstract
Thirteen children (ages 5.6 to 11.2 years) with autism and symptoms of attention-deficit hyperactivity disorder (ADHD) participated in a double-blind, placebo-controlled crossover study of methylphenidate (0.3 and 0.6 mg/kg per dose). Eight subjects responded positively, based upon a minimum 50% decrease on the Conners Hyperactivity Index. Ratings of stereotypy and inappropriate speech, which are often associated with autistic core features, also decreased. However, no changes were found on the Child Autism Rating Scale, a global assessment of autistic symptomotology. Significant adverse side effects occurred in some children including social withdrawal and irritability, especially at the 0.6 mg/kg dose. Results suggest that methylphenidate can be efficacious for children with autism and ADHD symptoms. However, this group of children seems to be particularly susceptible to adverse side effects.
Similar articles
- A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.Stein MA, et al.Pediatrics. 2003 Nov;112(5):e404. doi: 10.1542/peds.112.5.e404.Pediatrics. 2003.PMID:14595084Clinical Trial.
- Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.Firestone P, Musten LM, Pisterman S, Mercer J, Bennett S.Firestone P, et al.J Child Adolesc Psychopharmacol. 1998;8(1):13-25. doi: 10.1089/cap.1998.8.13.J Child Adolesc Psychopharmacol. 1998.PMID:9639076Clinical Trial.
- Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.Jain U, et al.J Clin Psychiatry. 2007 Feb;68(2):268-77. doi: 10.4088/jcp.v68n0213.J Clin Psychiatry. 2007.PMID:17335326Clinical Trial.
- Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.Epstein T, Patsopoulos NA, Weiser M.Epstein T, et al.Cochrane Database Syst Rev. 2014 Sep 18;(9):CD005041. doi: 10.1002/14651858.CD005041.pub2.Cochrane Database Syst Rev. 2014.Update in:Cochrane Database Syst Rev. 2016 May 26;(5):CD005041. doi: 10.1002/14651858.CD005041.pub3.PMID:25230710Updated.Review.
- [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].Golubchik P, Sever J, Weizman A.Golubchik P, et al.Harefuah. 2011 Oct;150(10):788-90, 814.Harefuah. 2011.PMID:22111124Review.Hebrew.
Cited by
- Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.Doyle CA, McDougle CJ.Doyle CA, et al.Dialogues Clin Neurosci. 2012 Sep;14(3):263-79. doi: 10.31887/DCNS.2012.14.3/cdoyle.Dialogues Clin Neurosci. 2012.PMID:23226952Free PMC article.Review.
- Concerns expressed by parents of children with pervasive developmental disorders for different time periods of the day: a case-control study.Sasaki Y, Usami M, Sasayama D, Okada T, Iwadare Y, Watanabe K, Ushijima H, Tanaka T, Harada M, Tanaka H, Kodaira M, Sugiyama N, Sawa T, Saito K.Sasaki Y, et al.PLoS One. 2015 Apr 21;10(4):e0124692. doi: 10.1371/journal.pone.0124692. eCollection 2015.PLoS One. 2015.PMID:25898260Free PMC article.
- ADHD symptom subtypes in children with pervasive developmental disorder.Gadow KD, DeVincent CJ, Pomeroy J.Gadow KD, et al.J Autism Dev Disord. 2006 Feb;36(2):271-83. doi: 10.1007/s10803-005-0060-3.J Autism Dev Disord. 2006.PMID:16477513
- Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.Holdman R, Vigil D, Robinson K, Shah P, Contreras AE.Holdman R, et al.Cannabis Cannabinoid Res. 2022 Aug;7(4):451-463. doi: 10.1089/can.2020.0154. Epub 2021 Aug 24.Cannabis Cannabinoid Res. 2022.PMID:34432543Free PMC article.
- Sedation After a Trial of Mixed Amphetamine Salts in a Boy with Attention-Deficit/Hyperactivity Disorder.Al Awami R, Albanna A.Al Awami R, et al.Am J Case Rep. 2020 Dec 17;21:e928269. doi: 10.12659/AJCR.928269.Am J Case Rep. 2020.PMID:33328428Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical